YBX1 and hepatocellular carcinoma: Moreover, extensive research has presented compelling evidence highlighting the pivotal involvement of YBX1 in the progression, metastasis, and development of drug resistance across diverse cancer types, including lung squamous cell carcinoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma (HCC), renal cell carcinoma, and nasopharyngeal carcinoma (16–21).